Germany indapamide market is estimated to grow significantly at a CAGR of around 3.6% during the forecast period. Due to the massive population of CVD, CHD, stroke, and rise in the adoption of indapamide drugs, the market is projected to grow considerably during the forecast period in Germany. The country has a quality healthcare system coupled with the cohesive government policies, that are driving the market in the region. As per the Institute for Health Metrics and Evaluation, around 192,000 cases of strokes were registered in the country in 2017 with a slight increment from 2014. Ischemic stroke is the leading stroke among all others in the country. As per Stroke Alliance for Europe (SAFE), in 2017 the prevalence of stroke was around 527,000 which is around 338 per 100,000 people. These high number of strokes prevalence in the country further increases the demand for indapamide in the country as it is used as the preventive treatment of stroke.
To Request a Sample of our Report on Germany Indapamide Market: https://www.omrglobal.com/request-sample/germany-indapamide-market
Germany indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
(Get 15% Discount on Buying this Report)
A full Report of Germany Indapamide Market is Available at: https://www.omrglobal.com/industry-reports/germany-indapamide-market
Germany Indapamide Market Segmentation
By Product
- 1.25 MG
- 2.5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
